Cart
sales@molnova.com
Tariquidar
CAS No. 206873-63-4
Tariquidar ( XR 9576;XR-9576;XR9576 )
Catalog No. M13215 CAS No. 206873-63-4
A potent, specific P-gp inhibitor with Kd of 5.1 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 119 | In Stock |
|
| 50MG | 215 | In Stock |
|
| 100MG | 361 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTariquidar
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, specific P-gp inhibitor with Kd of 5.1 nM.
-
DescriptionA potent, specific P-gp inhibitor with Kd of 5.1 nM; potentiates the cytotoxicity of several drugs including doxorubicin, paclitaxel, etoposide, and vincristine in a panel of human MDR cell lines at 25-80 nM; exhibits potent i.v. and p.o. activity without apparently enhancing the plasma pharmacokinetics of paclitaxel or the toxicity of coadministered drugs.Breast Cancer Phase 2 Discontinued
-
SynonymsXR 9576;XR-9576;XR9576
-
PathwayMembrane Transporter/Ion Channel
-
TargetP-glycoprotein
-
RecptorP-gp(P-glycoprotein)
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number206873-63-4
-
Formula Weight646.73
-
Molecular FormulaC38H38N4O6
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 100 mg/mL
-
SMILESCOC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=C(NC(=O)C5=CC6=CC=CC=C6N=C5)C=C(OC)C(OC)=C4)C=C3)CC2)C=C1OC |c:17,26,28,31,40,43,49,t:2,4,10,12,22,24,34|
-
Chemical Name3-Quinolinecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Martin C, et al. Br J Pharmacol. 1999 Sep;128(2):403-11.
2. Mistry P, et al. Cancer Res. 2001 Jan 15;61(2):749-58.
3. Walker J, et al. Eur J Cancer. 2004 Mar;40(4):594-605.
2. Mistry P, et al. Cancer Res. 2001 Jan 15;61(2):749-58.
3. Walker J, et al. Eur J Cancer. 2004 Mar;40(4):594-605.
molnova catalog
related products
-
Elacridar
A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
-
Dofequidar fumarate
A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.
-
Tariquidar methanesu...
A potent, specific P-gp inhibitor with Kd of 5.1 nM.
